Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| NASDAQ | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
LONDON (Reuters) – AstraZeneca said on Friday it was hopeful its antibody cocktail against COVID-19 would retain efficacy against a new variant that is spreading in South...
Hutchmed (China) (HCM) and AstraZeneca (AZN) have initiated SACHI, a China Phase III study of Orpathys (savolitinib) in combination with AstraZeneca’s Tagrisso (osimertinib)...
— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET —HONG KONG and...
Los Angeles, USA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Renal Cell Carcinoma Clinical Trials | A Drug Pipeline Analysis Report 2021 | DelveInsightThere are around 80+ key companies...
Europeans Vaccinated With AstraZeneca Should Be Able To Enter US, Says EUAuthored by Lorenz Duschamps via The Epoch Times,People who have received two doses of...
Los Angeles, USA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ovarian Cancer Clinical Trials | A Drug Pipeline Analysis Report 2021 | DelveInsightAround 100+ key companies are...
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 54.00 | 54.94 | 53.25 | +3.11 | +6.11% | 66.54M | NYSE | |||
| 156.81 | 160.45 | 156.36 | -5.13 | -3.17% | 76.09M | NASDAQ | |||
| 333.12 | 337.75 | 331.90 | -7.94 | -2.33% | 14.69M | NASDAQ | |||
| 2,843.70 | 2,891.10 | 2,836.90 | -78.7 | -2.69% | 1.52M | NASDAQ | |||
| 39.99 | 40.34 | 39.10 | -1.43 | -3.45% | 30.45M | NYSE | |||
| 315.03 | 327.10 | 313.50 | -11.71 | -3.58% | 27.54M | NASDAQ | |||
| 37.63 | 38.16 | 36.13 | -1.26 | -3.24% | 19.71M | NYSE | |||
| 665.64 | 676.41 | 660.67 | +7.35 | +1.12% | 2.87M | NASDAQ | |||
| 199.72 | 211.73 | 199.20 | -12.06 | -5.69% | 1.23M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 3,504.56 | 3,633.50 | 3,504.15 | -75.85 | -2.12% | 2.99M | NASDAQ | |||
| 69.47 | 70.78 | 69.18 | -1.17 | -1.66% | 3.72M | NYSE | |||
| 48.78 | 49.17 | 48.12 | -0.98 | -1.97% | 25.26M | NASDAQ | |||
| 19.38 | 19.83 | 19.22 | -0.01 | -0.05% | 13.97M | NYSE | |||
| 0.2515 | 0.00 | 0.00 | -0.0125 | -4.73% | 3.39M | NYSE |